Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib

被引：0
|
作者：
Zwierenga, F. [1 ]
Muntinghe-Wagenaar, B. [1 ]
Rozendal, P. [1 ]
van der Leest, P. [1 ]
Schuuring, E. [1 ]
van der Wekken, A. J. [1 ]
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
ctDNA; EGFR exon 20; resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.06D.02
引用
收藏
页码：S502 / S502
页数：1
相关论文
共 50 条
  • [1] Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with EGFR exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib.
    Vincent, Sylvie
    Su, Zhenqiang
    Bunn, Veronica
    Joshi, Adarsh
    Yu, Ziji
    Chatterjee, Sampurna
    Guha, Minakshi
    Zhang, Pingkuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib
    Rojas, L.
    Zuluaga, J.
    Ruiz-Patino, A.
    Rodriguez, J.
    Arrieta, O.
    Chamorro, D.
    Corrales, L.
    Martin, C.
    Viola, L.
    Raez, L.
    Vargas, C.
    Otero, J.
    Carranza, H.
    Motta, R.
    Cruz, G.
    Valencia, A.
    Rolfo, C.
    Rossell, R.
    Cardona, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S681 - S681
  • [3] Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib
    Wang, M.
    Fan, Y.
    Sun, M.
    Wang, Y.
    Zhao, Y.
    Jin, B.
    Hu, Y.
    Han, Z.
    Song, X.
    Liu, A.
    Tang, K.
    Ding, C.
    Liang, L.
    Wu, L.
    Gao, J.
    Wang, J.
    Cheng, Y.
    Zhou, J.
    He, Y.
    Dong, X.
    Yao, Y.
    Yu, Y.
    Wang, H.
    Sun, S.
    Huang, J.
    Fang, J.
    Li, W.
    Wang, L.
    Ren, X.
    Zhou, C.
    Hu, Y.
    Zhao, D.
    Yang, R.
    Xu, F.
    Huang, Y.
    Pan, Y.
    Cui, J.
    Xu, Y.
    Zhu, X.
    Shi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S150 - S150
  • [4] Study of patients' characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC
    Auclin, E.
    Du Rusquec, P.
    Albarran, V.
    Aboubakar, F.
    Gerber, H.
    Epaillard, N.
    Recondo, G.
    Berthou, H.
    Fabre-Guillevin, E.
    Laguna Montes, J. C.
    Blaquier, J. B.
    Jimenez Munarriz, B. E.
    Tagliamento, M.
    Sacco, G.
    Minatta, J. N.
    Girard, N.
    Moran Bueno, M. T.
    Lopez Castro, R.
    Besse, B.
    Mezquita, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1078 - S1078
  • [5] Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC
    van Veggel, Bianca
    de Langen, Adrianus J.
    Hashemi, Sayed M. S.
    Monkhorst, Kim
    Heideman, Danielle A. M.
    Thunnissen, Erik
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1222 - 1226
  • [6] Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
    Yamaguchi, Ou
    Kasahara, Norimitsu
    Soda, Hiroshi
    Imai, Hisao
    Naruse, Ichiro
    Yamaguchi, Hiroyuki
    Itai, Miki
    Taguchi, Kohei
    Uchida, Megumi
    Sunaga, Noriaki
    Maeno, Toshitaka
    Minato, Koichi
    Tomono, Hiromi
    Ogawara, Daiki
    Mukae, Hiroshi
    Miura, Yu
    Shiono, Ayako
    Mouri, Atsuto
    Kagamu, Hiroshi
    Kaira, Kyoichi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [7] Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
    Ou Yamaguchi
    Norimitsu Kasahara
    Hiroshi Soda
    Hisao Imai
    Ichiro Naruse
    Hiroyuki Yamaguchi
    Miki Itai
    Kohei Taguchi
    Megumi Uchida
    Noriaki Sunaga
    Toshitaka Maeno
    Koichi Minato
    Hiromi Tomono
    Daiki Ogawara
    Hiroshi Mukae
    Yu Miura
    Ayako Shiono
    Atsuto Mouri
    Hiroshi Kagamu
    Kyoichi Kaira
    Scientific Reports, 13
  • [8] Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for advanced NSCLC with EGFR-positive mutation patients: A systematic review
    Chen, S.
    Marcella, E.
    Susanto, B.
    Tandiono, J.
    Heriyanto, R. S.
    Wijovi, F.
    Tancherla, A.
    Kurniawan, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S779 - S780
  • [9] High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20
    Zwierenga, F.
    van Veggel, B. A. M. H.
    Hendriks, L. E. L.
    Hiltermann, T. J. N.
    Hiddinga, B. I.
    Hijmering-Kappelle, L. B. M.
    Dingemans, A-M. C.
    van der Leest, C.
    de langen, A. J.
    van den Heuvel, M.
    van der Wekken, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S966 - S966
  • [10] High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
    Zwierenga, Fenneke
    van Veggel, Bianca
    Hendriks, Lizza E. L.
    Hiltermann, T. Jeroen N.
    Hiddinga, Birgitta I.
    Kappelle, Lucie B. M. Hijmering
    ter Elst, Arja
    Hashemi, Sayed M. S.
    Dingemans, Anne-Marie C.
    van der Leest, Cor
    de Langen, Adrianus J.
    van den Heuvel, Michel M.
    van der Wekken, Anthonie J.
    LUNG CANCER, 2022, 170 : 133 - 140
12345